Opportunity Information: Apply for PAR 13 001
Apply for PAR 13 001
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition Continuation of the National Institute on Aging Multicenter Clinical Trial The LIFE Study (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Oct 5, 2012 and posted on Oct 5, 2012.
- Applicants must submit their applications by Apr 26, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Faith based or Community based Organizations The only eligible organizations are the current recipients of the LIFE Study award (U01AG022376) Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity PAR 13 001, titled "Limited Competition Continuation of the National Institute on Aging Multicenter Clinical Trial The LIFE Study (U01)," is a National Institutes of Health (NIH) cooperative agreement intended to support the continued operation and follow-up of an existing, large multicenter clinical trial known as The LIFE Study. The administering institute is the National Institute on Aging (NIA), and the program sits within the NIH health research portfolio under CFDA 93.866 (Aging Research). This is not a new, open competition for launching a fresh trial; it is explicitly structured as a limited competition designed to extend and build on the work already underway under the original LIFE Study award.
At its core, The LIFE Study was created to answer a practical, high-impact question for older adults: whether a long-term, structured physical activity program can prevent or delay major mobility disability compared with an alternative program focused on health education. In this trial, major mobility disability is defined using a clear functional benchmark, the inability to walk 400 meters, which is widely used in aging research because it reflects real-world independence and predicts downstream outcomes like institutionalization, hospitalization, and mortality risk. The comparison condition in the study is described as a "successful aging" (SA) health education program, providing a credible and active comparator rather than a no-treatment control, which strengthens the relevance of results for public health and clinical practice.
The continuation or extension supported by this FOA is aimed at expanding what can be learned from the existing LIFE Study cohort and infrastructure. While the original primary endpoint focused on major mobility disability, the extension is meant to determine how sustained participation in the structured physical activity intervention affects other diseases and conditions that matter greatly in later life. Specifically highlighted outcomes include mild cognitive impairment and dementia, cardiovascular disease, and persistent major mobility disability, along with other age-related outcomes not exhaustively listed in the summary. The intent is to leverage the established multicenter trial platform, participants, and operational systems to evaluate longer-term and broader health effects that may take more time to emerge or require extended follow-up to measure reliably.
From an administrative and eligibility standpoint, this FOA is highly restricted. The only eligible applicants are the current recipients of the LIFE Study award identified as U01AG022376. In other words, the competition is limited to the existing awardee organization(s) already conducting the LIFE Study, rather than being open to the wider research community. The eligibility text also notes that faith-based or community-based organizations are considered "other eligible applicants" in general, but in this specific announcement the decisive restriction is that only the current LIFE Study award recipients may apply. Foreign (non-U.S.) institutions are not eligible to apply as applicant organizations; however, non-domestic components of U.S. organizations may participate, and foreign components are allowed as defined by the NIH Grants Policy Statement. No cost sharing or matching is required.
The award mechanism is a cooperative agreement (U01), which signals that NIH expects substantial scientific or programmatic involvement during the conduct of the work, beyond what is typical for a standard research project grant. Cooperative agreements are commonly used for complex, multi-site clinical trials where coordination, harmonization of procedures, and ongoing oversight are essential. The activity category is health, consistent with the clinical and public health nature of the study.
Key dates included a posted and created date of October 5, 2012, with an original and current closing date of April 26, 2013, and an archive date of May 27, 2013, indicating the opportunity is no longer active but remains important as a record of how the LIFE Study continuation was structured. The full announcement was available through NIH at the provided link (grants.nih.gov), and the contact information listed is oriented toward technical assistance with accessing or linking to the funding announcement via the NIH Office of Extramural Research (OER) webmaster.
In practical terms, the opportunity can be understood as NIH and NIA making a targeted investment to extend an already-running landmark trial in older adults, using a rigorous comparison of structured physical activity versus health education, and broadening the lens from mobility alone to a wider set of late-life outcomes such as cognitive decline and cardiovascular disease. The limited competition format underscores that the goal is continuity, consistency, and maximal scientific yield from an established multicenter clinical trial rather than starting new teams or new trial platforms from scratch.
Frequently Asked Questions (FAQ) - PAR-13-001 (LIFE Study Continuation, U01)
What is this funding opportunity?
This opportunity is NIH funding opportunity announcement PAR-13-001 titled "Limited Competition Continuation of the National Institute on Aging Multicenter Clinical Trial The LIFE Study (U01)." It supports the continued operation and follow-up of an existing large multicenter clinical trial known as The LIFE Study.
Which NIH institute is administering this opportunity?
The administering institute is the National Institute on Aging (NIA), within the National Institutes of Health (NIH).
Is this an open competition for new applicants?
No. This is explicitly a limited competition and is not intended to launch a new trial or bring in new teams to start a fresh study platform.
Who is eligible to apply?
Only the current recipients of the LIFE Study award identified as U01AG022376 are eligible to apply under this announcement.
Are foreign (non-U.S.) institutions eligible to apply as applicant organizations?
No. Foreign institutions are not eligible to apply as applicant organizations for this FOA.
Can foreign components participate in any way?
Yes. Non-domestic components of U.S. organizations may participate, and foreign components are allowed as defined by the NIH Grants Policy Statement.
Does this opportunity require cost sharing or matching funds?
No. The announcement states that no cost sharing or matching is required.
What is the funding mechanism used for this award?
The mechanism is a cooperative agreement (U01). This mechanism is commonly used for complex, multi-site clinical trials where ongoing coordination and oversight are important.
What does a cooperative agreement (U01) imply about NIH involvement?
A U01 cooperative agreement signals that NIH expects substantial scientific or programmatic involvement during the conduct of the work, beyond what is typical for a standard research project grant.
What is the LIFE Study trying to determine?
The LIFE Study was designed to answer whether a long-term, structured physical activity program can prevent or delay major mobility disability in older adults, compared with an alternative program focused on health education.
What intervention is being tested in the LIFE Study?
The trial tests a long-term, structured physical activity program.
What is the comparison or control condition in the trial?
The comparison condition is a "successful aging" (SA) health education program. It serves as an active, credible comparator rather than a no-treatment control.
How is major mobility disability defined in this study?
Major mobility disability is defined as the inability to walk 400 meters. This benchmark is widely used in aging research because it reflects real-world independence and predicts outcomes such as institutionalization, hospitalization, and mortality risk.
What is the main purpose of the continuation/extension supported by this FOA?
The continuation is intended to extend and build on work already underway by expanding what can be learned from the existing LIFE Study cohort and infrastructure, including longer-term follow-up and broader outcomes.
What additional outcomes are highlighted for the extension?
Beyond the original focus on major mobility disability, the extension specifically highlights outcomes including mild cognitive impairment and dementia, cardiovascular disease, and persistent major mobility disability, along with other age-related outcomes.
Why is NIH using a limited competition format here?
The limited competition format reflects a goal of continuity and consistency in an already-running, landmark multicenter clinical trial, aiming to maximize scientific yield from an established cohort, procedures, and operational systems.
What is the CFDA number and program area associated with this opportunity?
The opportunity is listed under CFDA 93.866, Aging Research, within the NIH health research portfolio.
What is the activity category for this announcement?
The activity category is health, consistent with the clinical and public health focus of the LIFE Study.
When was this opportunity posted and when did it close?
The posted/created date is October 5, 2012. The original and current closing date is April 26, 2013.
Is this funding opportunity still active?
No. The archive date is May 27, 2013, indicating the opportunity is no longer active and is available primarily as a record of how the LIFE Study continuation was structured.
Where was the full announcement made available?
The full announcement was available through NIH on grants.nih.gov.
Who was listed as the contact for assistance?
The contact information provided is oriented toward technical assistance with accessing or linking to the funding announcement via the NIH Office of Extramural Research (OER) webmaster.
Browse more opportunities from the same category: Health
Next opportunity: Fall 2013 EPA Science to Achieve Results (STAR) Fellowships for Graduate Environmental Study
Previous opportunity: Tunisia Undergraduate Scholarship Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| TECHNICAL ASSISTANCE AND SUPPORT OF HIV PREVENTION, CARE TREATMENT PROGRAMS AND OTHER INFECTIOUS DISEASES THAT IMPACT HIV INFECTED PATIENTS IN SUPPORT OF THE PRESIDENTS EMERGENCY PLAN FOR AIDS RELIEF Apply for CDC RFA PS09 9040401SUPP13 Funding Number: CDC RFA PS09 9040401SUPP13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $635,768 |
| Presidents Malaria Initiative Apply for USAID GUINEA RFA 675 13 000001 Funding Number: USAID GUINEA RFA 675 13 000001 Agency: Senegal USAID Dakar Category: Health Funding Amount: $18,428,129 |
| Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimers Disease (R01) Apply for RFA AG 13 013 Funding Number: RFA AG 13 013 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Alzheimers Disease Prevention Trials (R01) Apply for RFA AG 13 015 Funding Number: RFA AG 13 015 Agency: National Institutes of Health Category: Health Funding Amount: $4,500,000 |
| Alzheimers Disease Phase I Clinical Trials (R01) Apply for RFA AG 13 016 Funding Number: RFA AG 13 016 Agency: National Institutes of Health Category: Health Funding Amount: $800,000 |
| Shared Instrumentation Grant Program (S10) Apply for PAR 13 008 Funding Number: PAR 13 008 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Dynamics of Host Associated Microbial Communities (R01) Apply for RFA GM 14 001 Funding Number: RFA GM 14 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Secondary Dataset Analyses in Heart, Lung, and Blood Diseases and Sleep Disorders (R21) Apply for PAR 13 009 Funding Number: PAR 13 009 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| Mentored Research Scientist Development Award in Metabolomics (K01) Apply for RFA RM 12 025 Funding Number: RFA RM 12 025 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Health System Strengthening Project Apply for APS 391 13 000001 Funding Number: APS 391 13 000001 Agency: Pakistan USAID Islamabad Category: Health Funding Amount: $21,900,000 |
| Limited Competition Brain Tissue Resource Center for Alcohol Research (R28) Apply for PAR 13 011 Funding Number: PAR 13 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Initiative to Maximize Research Education in Genomics Courses (R25) Apply for PAR 13 012 Funding Number: PAR 13 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Agir pour la Planification Familiale AGIR PF Apply for RFA 624 13 000002 Funding Number: RFA 624 13 000002 Agency: Ghana USAID Accra Category: Health Funding Amount: $29,000,000 |
| Alzheimers Disease Therapeutics Program (U01) Apply for RFA AG 13 014 Funding Number: RFA AG 13 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epigenomics of Virus Associated Oral Diseases (R21) Apply for RFA DE 13 003 Funding Number: RFA DE 13 003 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Epigenomics of Virus Associated Oral Diseases (R01) Apply for RFA DE 13 002 Funding Number: RFA DE 13 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Collaborative Network for Clinical Research on Immune Tolerance (UM1) Apply for RFA AI 12 043 Funding Number: RFA AI 12 043 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tuberculosis Research Units (U19) Apply for RFA AI 12 045 Funding Number: RFA AI 12 045 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Conference Grant Program (R13) Apply for PA 13 017 Funding Number: PA 13 017 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Limited Competition Collaborative Partnership to Advance Global Biomedical Research Programs (U01) Apply for RFA AI 12 055 Funding Number: RFA AI 12 055 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.